logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r.png
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

MORSE Consulting Releases its pCPA Quarterly Update – Q1 2022

May 5, 2022
-
Market Access News, Publications
-
Posted by MORSE - < 1 min read.

MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. We extend our gratitude to those who provided feedback in anticipation for the transition to a quarterly update.

We are pleased to release our first Quarterly pCPA Update Infographic. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from this past quarter. By analyzing quarterly vs. monthly data we will be better able to identify important trends and provide useful insights to the market access community.

This infographic compares 2022’s Q1 metrics to those prior, sharing MORSE’s insights on:

  • pCPA activity;
  • files under consideration;
  • files under negotiation
  • pCPA capacity

For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report.

 

Click on graphic to print or see full-size OR download PDF.

 

Please contact info@morseconsulting.ca regarding any questions on this infographic or on the CRaFT report.

Embed this infographic (cut and paste code) on your website with attribution:

 

 

To receive updates similar to this one, please sign up for MORSE Signals, our free e-mail newsletter service.

Share
Tags
Biosimilars
CADTH
COVID-19
CRaFT
DRD
Forecasting
Market Access
Oncology
Pan Canadian Pharmaceutical Alliance
Pandemic
pCPA
pCPAO
Reimbursement
← PREVIOUS POST
MORSE Consulting Releases its pCPA Quarterly Update - Q2 2022
NEXT POST →
The End of Clinical Summaries?

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
MORSE Consulting Releases its pCPA Quarterly Update - Q1 2022